Projects per year
Frailty stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma – the FRAIL-M study
3/01/19 → 30/09/23
An exploratory study of venetoclax in combination with bortezomib-cyclophosphamide-dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies.
Spencer, A., Kennedy, N., Mollee, P., Harrison, S. J., Quach, H. & Ho, J.
27/09/18 → 27/09/23
5/12/17 → 5/04/21